Non-Hodgkin lymphoma incidence statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Cases

New cases of non-Hodgkin lymphoma, 2015-2017, UK

 

Proportion of all cases

Percentage non-Hodgkin lymphoma is of total cancer cases, 2015-2017, UK

 

Age

Peak rate of non-Hodgkin lymphoma cases, 2015-2017, UK

 

Trend over time

Change in non-hodgkin lymphoma incidence rates since the early 1990s, UK

 

Non-Hodgkin lymphoma is the 6th most common cancer in the UK, accounting for 4% of all new cancer cases (2017).[1-4]

In females in the UK, non-Hodgkin lymphoma is the 7th most common cancer (4% of all new female cancer cases). In males in the UK, it is the 7th most common cancer (4% of all new male cancer cases).

45% of non-Hodgkin lymphoma cases in the UK are in females, and 55% are in males

Non-Hodgkin lymphoma incidence rates (European age-standardised (AS) rates Open a glossary item) for persons are significantly lower than the UK average in Scotland and Wales, and similar to the UK average in all other UK constituent countries.

Non-Hodgkin Lymphoma (C82-C86), Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK, 2017

  England Scotland Wales Northern Ireland UK
Female Cases 5,411 489 265 147 6,312
Crude Rate 19.2 17.6 16.7 15.5 18.9
AS Rate 19.5 17.0 15.3 16.7 19.0
AS Rate - 95% LCL 19.0 15.5 13.4 14.0 18.5
AS Rate - 95% UCL 20.0 18.5 17.1 19.4 19.5
Male Cases 6,654 547 389 197 7,787
Crude Rate 24.2 20.7 25.3 21.4 23.9
AS Rate 27.6 22.9 26.1 26.2 27.0
AS Rate - 95% LCL 26.9 21.0 23.5 22.5 26.4
AS Rate - 95% UCL 28.2 24.8 28.7 29.9 27.6
Persons Cases 12,065 1,036 654 344 14,099
Crude Rate 21.7 19.1 20.9 18.4 21.3
AS Rate 23.2 19.7 20.2 21.1 22.7
AS Rate - 95% LCL 22.8 18.5 18.7 18.8 22.3
AS Rate - 95% UCL 23.6 20.9 21.8 23.3 23.1

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item
 

For non-Hodgkin lymphoma, there are few established risk factors therefore differences between countries largely reflect differences in diagnosis and data recording.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, August 2018. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2018. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, February 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, April 2018. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2017, ICD-10 C82-C86.

The term 'non-Hodgkin lymphoma' describes a large group of lymphoma subtypes, which differ substantially in their cellular origin and clinical behaviour. The subtypes can be broadly divided into B-cell lymphomas, T-cell lymphomas, and lymphoproliferative disorders not otherwise specified. B-cell lymphomas can be further divided into five main types: diffuse large B-cell lymphoma, marginal zone lymphomas, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. It is important to recognise the variation between these subtypes when interpreting statistics on NHL as a whole. The Haematological Malignancy Research Network provides detailed incidence statistics for NHL subtypes.

Last reviewed:

Non-Hodgkin lymphoma incidence is strongly related to age, with the highest incidence rates being in older people.

In the UK in 2015-2017, on average each year more than a third of new cases (36%) were in people aged 75 and over.[1-4]

Age-specific incidence rates rise steadily from around age 45-49 and more steeply from around age 55-59.The highest rates are in in the 80 to 84 age group for females and the 85 to 89 age group for males.

Incidence rates are significantly lower in females than males in most age groups.The gap is widest at age 15 to 19, when the age-specific incidence rate is 2.1 times lower in females than males.

Non-Hodgkin lymphoma (C82-C86), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Population, UK, 2015-2017

For non-Hodgkin lymphoma, like most cancer types, incidence increases with age. This largely reflects cell DNA damage accumulating over time. Damage can result from biological processes or from exposure to risk factors. A drop or plateau in incidence in the oldest age groups often indicates reduced diagnostic activity perhaps due to general ill health.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2015-2017, C82-C86.

The term 'non-Hodgkin lymphoma' describes a large group of lymphoma subtypes, which differ substantially in their cellular origin and clinical behaviour. The subtypes can be broadly divided into B-cell lymphomas, T-cell lymphomas, and lymphoproliferative disorders not otherwise specified. B-cell lymphomas can be further divided into five main types: diffuse large B-cell lymphoma, marginal zone lymphomas, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. It is important to recognise the variation between these subtypes when interpreting statistics on NHL as a whole. The Haematological Malignancy Research Network provides detailed incidence statistics for NHL subtypes.

Last reviewed:

Non-Hodgkin lymphoma European age-standardised (AS) incidence rates for females and males combined increased by 39% in the UK between 1993-1995 and 2015-2017.[1-4] The increase was of a similar size in females and males.

For females, non-Hodgkin lymphoma AS incidence rates in the UK increased by 39% between 1993-1995 and 2015-2017. For males, non-Hodgkin lymphoma AS incidence rates in the UK increased by 36% between 1993-1995 and 2015-2017.

Over the last decade in the UK (between 2005-2007 and 2015-2017), non-Hodgkin lymphoma AS incidence rates for females and males combined increased by 13%. In females AS incidence rates increased by 11%, and in males rates increased by 13%.

Non-Hodgkin Lymphoma (ICD-10 C82-C86), European Age-Standardised Incidence Rates, UK, 1993-2017

Non-Hodgkin lymphoma incidence rates have increased overall in some broad age groups in females and males combined in the UK since the early 1990s, but have remained stable in others.[1-4] Rates in 0-24s have remained stable, in 25-49s have remained stable, in 50-59s have increased by 11%, in 60-69s have increased by 40%, in 70-79s have increased by 57%, and in 80+s have increased by 67%.

Non-Hodgkin Lymphoma (ICD-10 C82-C86), European Age-Standardised Incidence Rates, By Age, UK, 1993-2017

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 1993-2017, ICD-10 C82-C86.

The term 'non-Hodgkin lymphoma' describes a large group of lymphoma subtypes, which differ substantially in their cellular origin and clinical behaviour. The subtypes can be broadly divided into B-cell lymphomas, T-cell lymphomas, and lymphoproliferative disorders not otherwise specified. B-cell lymphomas can be further divided into five main types: diffuse large B-cell lymphoma, marginal zone lymphomas, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. It is important to recognise the variation between these subtypes when interpreting statistics on NHL as a whole. The Haematological Malignancy Research Network provides detailed incidence statistics for NHL subtypes.

Last reviewed:

Staging completeness for non-Hodgkin lymphoma is moderate in England, with 78% of non-Hodgkin lymphoma cases recorded with a known stage at diagnosis in 2014.[1]

Non-Hodgkin Lymphoma (C82-C85), Proportion of Cases Diagnosed at Each Stage, England 2014

People diagnosed with non-Hodgkin lymphoma with a known stage most commonly present at stage IV (45%), in England. More people with a known stage are diagnosed at an advanced stage (64% diagnosed at stage III or IV) than an early stage (36% diagnosed at stage I or II ).[1]

References

  1. National Cancer Registration and Analysis Service. Stage Breakdown by CCG 2014. London: NCRAS; 2016.

About this data

Data is for: England, 2014, ICD-10 C82-C85

Stage at diagnosis data is not yet routinely available for the UK due to inconsistencies in the collecting and recording of staging data in the past.

Last reviewed:

Non-Hodgkin lymphoma (NHL) incidence rates are projected to fall by 2% in the UK between 2014 and 2035, to 26 cases per 100,000 people by 2035.[1] This includes a smaller decrease for males than for females.

For males, non-Hodgkin lymphoma European age-standardised (AS) Open a glossary item incidence rates in the UK are projected to fall by 3% between 2014 and 2035, to 32 cases per 100,000 by 2035.[1] For females, rates are projected to fall by 3% between 2014 and 2035, to 22 cases per 100,000 by 2035.[1]

Non-Hodgkin lymphoma (C82-C85), Observed and Projected Age-Standardised Incidence Rates, by Sex, UK, 1979-2035

 

It is projected that 18,621 cases of non-Hodgkin lymphoma (10,489 in males, 8,132 in females) will be diagnosed in the UK in 2035.

References

  1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer Incidence and Mortality Projections in the UK Until 2035. Brit J Cancer 2016.

About this data

Data is for: UK, 1979-2014 (observed), 2015-2035 (projected), ICD-10 C82-C85

Projections are based on observed incidence and mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. It is not possible to assess the statistical significance of changes between 2014 (observed) and 2035 (projected) figures. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as 'increase' or 'decrease' if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

Non-Hodgkin lymphoma incidence rates (European age-standardised (AS) rates Open a glossary item) in England in females are similar in the most deprived quintile compared with the least, and in males are 10% lower in the most deprived quintile compared with the least (2013-2017).[1]

It is estimated that there are around 240 fewer cases of non-Hodgkin lymphoma each year in males in England than there would be if every deprivation quintile had the same age-specific crude incidence rates as the least deprived quintile.

Non-Hodgkin Lymphoma (C82-C86), Estimated Average Number of Fewer Cases per Year, by Deprivation Quintile, England, 2013-2017

Non-Hodgkin Lymphoma (C82-C86), European Age-Standardised Incidence Rates per 100,000 Population, by Deprivation Quintile, England, 2013-2017

References

  1. Calculated by the Cancer Intelligence Team at Cancer Research UK, April 2020. Based on method reported in National Cancer Intelligence Network Cancer by Deprivation in England Incidence, 1996-2010 Mortality, 1997-2011 . Using cancer incidence data 2013-2017 (Public Health England) and population data 2013-2017 (Office for National Statistics) by Indices of Multiple Deprivation 2015 income domain quintile, cancer type, sex, and five-year age band.

About this data

Data is for England, 2013-2017, ICD-10 C82-C86

Last reviewed:

Age-standardised Open a glossary item rates for White males with Non-Hodgkin lymphoma (ICD-10 C82-C85 and C96) range from 15.7 to 16.5 per 100,000. Rates for Asian males are similar, ranging from 10.3 to 16.9 per 100,000 and the rates for Black males are also similar, ranging from 11.4 to 19.6 per 100,000. For females there is a similar pattern - the age-standardised rates for White females range from 11.2 to 11.8 per 100,000 and rates for Asian and Black females are also similar ranging from 7.0 to 11.8 per 100,000 and 8.7 to 15.1 per 100,000 respectively.[1]

There appears to be no significant variation in Non-Hodgkin lymphoma incidence by ethnicity in the UK.[1,2] However, US data shows that since 1992, NHL rates have been significantly higher in non-Hispanic white people than in black people.[3]

Ranges are given because of the analysis methodology used to account for missing and unknown data. For Non-Hodgkin lymphoma, 42,576 cases were identified; 21% had no known ethnicity.

References

  1. National Cancer Intelligence Network (NCIN) and Cancer Research UK. Cancer Incidence and Survival by Major Ethnic Group, England, 2002-2006. London: NCIN; 2009.
  2. Ross JRY, Oliver SE. National Cancer Intelligence Network (NCIN) analyses of haematological malignancy. Incidence and survival by sex, ethnicity, deprivation, year of diagnosis and cancer network in the United Kingdom. Brit J Haematol 2010;149:57.
  3. Surveillance Epidemiology and End Results. Age-Adjusted SEER Incidence Rates and 95% Confidence Intervals; By Race/Ethnicity; Non-Hodgkin Lymphoma, All Ages, Both Sexes; 1992- 2009. Accessed at: http://seer.cancer.gov. Accessed September 2012.

About this data

Data is for England, 2002-2006, ICD-10 C82-C86.

Last reviewed:

An estimated 76,800 people who had been diagnosed with non-Hodgkin lymphoma (NHL) between 1991 and 2010 were alive in the UK at the end of 2010.[1]

References

  1. Macmillan Cancer Support and National Cancer Registration and Analysis Service. Cancer Prevalence UK Data Tables. London: NCRAS; 2015.

About this data

Data is for: Great Britain (1991-2010) and Northern Ireland (1993-2010), ICD-10 C82-C86

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.